Skip to main content
Premium Trial:

Request an Annual Quote

ActivX Biosciences Appoints Former Bayer Exec as VP of Chemistry

NEW YORK, May 24 - Proteomics startup ActivX Biosciences has appointed David Campbell, formerly director of discovery chemistry at Bayer, to the position of vice president of chemistry, the company said Thursday. 

At ActivX Campbell will be responsible for overseeing all chemistry programs at the company. 

Prior to working for Bayer, where he directed target discovery research in cancer and obesity, Campbell served as director of chemistry at Affymax Research Institute, a company with expertise in combinatorial chemistry and high-throughput screening.

"David Campbell is one of the new breed of young leaders in pharmaceutical chemistry," John Kozarich, ActivX's president and chief scientific officer, said in a statement. "His considerable accomplishments in the arenas of biotechnology and big pharma give him a unique perspective on discovery at the interface of chemistry and biology. He will be a major force in the application of ActivX chemistry to proteomics."

ActivX was founded last year by Robert Hillman, the company's CEO; Ben Cravatt, a faculty member at the Scripps Research Institute; and Jeffrey Smith, a member of the Burnham Institute. The company is developing a high-throughput platform for discovering medically-relevant proteins.  
The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.